MiMedx is a top growth pick for 2014 at Canaccord Canaccord named MiMedx a top growth pick for 2014 to reflect recent reimbursement changes, regulatory clarity on micronized products, Medtronic distribution agreement opportunity, and the positive coverage decision from the 6th MAC. Shares are Buy rated with a $12 price target raised from $8.
News For MDXG From The Last 14 Days
Check below for free stories on MDXG the last two weeks.
MiMedx was downgraded on January 6 at Northland Securities Shares of MiMedx are moving lower on incorrect reports that Northland Securities downgraded shares today. The firm downgraded shares on January 6 to Market Perform and maintains its rating.